Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Authors

Chen R.; Aamir A.H.; Feroz Amin M.; Bunnag P.; Chan S.P.; Guo L.; Khamseh M.E.; Mohan V.; Nicodemus N., Jr.; Roberts A.; Tarigan T.J.E.; Won K.-C.; Mehta R.

Author_Full_Names

Chen, Roger (22133762300); Aamir, Azizul Hasan (8514966600); Feroz Amin, Mohammod (58988742900); Bunnag, Pongamorn (6603062905); Chan, Siew Pheng (7404255462); Guo, Lixin (55018577700); Khamseh, Mohammad E. (18134374500); Mohan, Viswanathan (35509595400); Nicodemus, Nemencio (8315235700); Roberts, Anthony (56408760700); Tarigan, Tri Juli Edi (36057746500); Won, Kyu-Chang (57206373141); Mehta, Roopa (56245541000)

Author S Id

22133762300; 8514966600; 58988742900; 6603062905; 7404255462; 55018577700; 18134374500; 35509595400; 8315235700; 56408760700; 36057746500; 57206373141; 56245541000

Title

Barriers to the Use of Insulin Therapy and Potential Solutions: A Narrative Review of Perspectives from the Asia–Pacific Region

Year

2024

Source Title

Diabetes Therapy

Volume

Issue

Art No

Page Start

1261

Page End

1277

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190520340&doi=10.1007%2fs13300-024-01568-9&partnerID=40&md5=2fd03262106ba526e5c5c46b64fd4b72

Affiliations

Department of Endocrinology, St Vincent’s Hospital, 406 Victoria Street, Darlinghurst, Sydney, 2010, NSW, Australia; University of New South Wales, Sydney, Australia; Department of Diabetes, Endocrinology and Metabolic Diseases, MTI Hayatabad Medical Complex, Peshawar, Pakistan; Department of Endocrinology and Metabolic Disease, BIRDEM Hospital, Dhaka, Bangladesh; Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia; Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China; Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran; Madras Diabetes Research Foundation and Dr. Mohan’s Diabetes Specialities Centre, Chennai, India; Department of Biochemistry and Molecular Biology, University of the Philippines-College of Medicine, Manila, Philippines; South Australian Endocrine Clinical Research, Keswick, Adelaide, SA, Australia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea; Unidad de Investigación en Enfermedades Metabólicas, Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Authors With Affiliations

Chen R., Department of Endocrinology, St Vincent’s Hospital, 406 Victoria Street, Darlinghurst, Sydney, 2010, NSW, Australia, University of New South Wales, Sydney, Australia; Aamir A.H., Department of Diabetes, Endocrinology and Metabolic Diseases, MTI Hayatabad Medical Complex, Peshawar, Pakistan; Feroz Amin M., Department of Endocrinology and Metabolic Disease, BIRDEM Hospital, Dhaka, Bangladesh; Bunnag P., Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Chan S.P., Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia; Guo L., Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China; Khamseh M.E., Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran; Mohan V., Madras Diabetes Research Foundation and Dr. Mohan’s Diabetes Specialities Centre, Chennai, India; Nicodemus N., Jr., Department of Biochemistry and Molecular Biology, University of the Philippines-College of Medicine, Manila, Philippines; Roberts A., South Australian Endocrine Clinical Research, Keswick, Adelaide, SA, Australia; Tarigan T.J.E., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Won K.-C., Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea; Mehta R., Unidad de Investigación en Enfermedades Metabólicas, Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Abstract

The rising prevalence of type 2 diabetes (T2D) is posing major challenges for the healthcare systems of many countries, particularly in the Asia–Pacific Region, in which T2D can present at younger ages and lower body mass index when compared with Western nations. There is an important role for insulin therapy in the management of T2D in these nations, but available evidence suggests that insulin is under-utilized and often delayed, to the detriment of patient prognosis. The authors of this article gathered as an advisory panel (representative of some of the larger Asia–Pacific nations) to identify their local barriers to insulin use in T2D, and to discuss ways in which to address these barriers, with their outputs summarized herein. Many of the key barriers identified are well-documented issues of global significance, including a lack of healthcare resources or of an integrated structure, insufficient patient education, and patient misconceptions about insulin therapy. Barriers identified as more innate to Asian countries included local inabilities of patients to afford or gain access to insulin therapy, a tendency for some patients to be more influenced by social media and local traditions than by the medical profession, and a willingness to switch care providers and seek alternative therapies. Strategies to address some of these barriers are provided, with hypothetical illustrative case histories. © The Author(s) 2024.

Author Keywords

Asia–Pacific region; Barriers; Insulin therapy; Patient education; Type 2 diabetes

Index Keywords

glucagon like peptide 1; insulin; insulin pump; sodium glucose cotransporter 2; blood glucose monitoring; clinical practice; glycemic control; health care personnel; health care system; health service; human; insulin treatment; non insulin dependent diabetes mellitus; patient education; phenotype; physician; prevalence; prognosis; Review; training

Funding Details

Edward Potts and Helen Marshall, of Ashfield MedComms; Novo Nordisk

Funding Text

Support for the development of this manuscript, under the direction of the authors, was provided by Edward Potts and Helen Marshall, of Ashfield MedComms, an Inizio company, and funded by Novo Nordisk. Drafts of the article were prepared by a medical writer, funded by the sponsor, and were circulated to all authors for review. The sponsor reviewed the final draft of the article for medical accurac

Publisher

Adis

Issn

18696953

Isbn

Pubmed Id

Document Type

Review

Sjr Best Quartile

Sjr

1039

Sjr Rank

3963